Oryzon Genomics S.A. (BME:ORY)

Oryzon Genomics Statistics

Total Valuation

Oryzon Genomics has a market cap or net worth of EUR 268.89 million. The enterprise value is 255.90 million.

Market Cap	268.89M
Enterprise Value	255.90M

Important Dates

The last earnings date was Monday, October 27, 2025.

Earnings Date	Oct 27, 2025
Ex-Dividend Date	n/a

Share Statistics

Oryzon Genomics has 78.85 million shares outstanding. The number of shares has increased by 23.15% in one year.

Current Share Class	78.85M
Shares Outstanding	78.85M
Shares Change (YoY)	+23.15%
Shares Change (QoQ)	+19.72%
Owned by Insiders (%)	15.26%
Owned by Institutions (%)	-0.66%
Float	66.82M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	35.99
PB Ratio	2.35
P/TBV Ratio	2.36
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	-60.64
EV / Sales	34.25
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 2.62, with a Debt / Equity ratio of 0.16.

Current Ratio	2.62
Quick Ratio	2.62
Debt / Equity	0.16
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	-4.86

Financial Efficiency

Return on equity (ROE) is -4.20% and return on invested capital (ROIC) is -2.65%.

Return on Equity (ROE)	-4.20%
Return on Assets (ROA)	-2.52%
Return on Invested Capital (ROIC)	-2.65%
Return on Capital Employed (ROCE)	-4.01%
Revenue Per Employee	158,959
Profits Per Employee	-89,785
Employee Count	47
Asset Turnover	0.06
Inventory Turnover	42.35

Taxes

Income Tax	-1.31M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +97.06% in the last 52 weeks. The beta is 0.45, so Oryzon Genomics's price volatility has been lower than the market average.

Beta (5Y)	0.45
52-Week Price Change	+97.06%
50-Day Moving Average	3.08
200-Day Moving Average	2.71
Relative Strength Index (RSI)	55.87
Average Volume (20 Days)	1,901,074

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Oryzon Genomics had revenue of EUR 7.47 million and -4.22 million in losses. Loss per share was -0.05.

Revenue	7.47M
Gross Profit	7.19M
Operating Income	-5.03M
Pretax Income	-5.53M
Net Income	-4.22M
EBITDA	-4.92M
EBIT	-5.03M
Loss Per Share	-0.05

Balance Sheet

The company has 31.11 million in cash and 18.12 million in debt, giving a net cash position of 12.99 million or 0.16 per share.

Cash & Cash Equivalents	31.11M
Total Debt	18.12M
Net Cash	12.99M
Net Cash Per Share	0.16
Equity (Book Value)	114.22M
Book Value Per Share	1.47
Working Capital	21.13M

Cash Flow

Operating Cash Flow	-3.03M
Capital Expenditures	n/a
Free Cash Flow	n/a
FCF Per Share	n/a

Margins

Gross margin is 96.27%, with operating and profit margins of -67.30% and -56.48%.

Gross Margin	96.27%
Operating Margin	-67.30%
Pretax Margin	-74.01%
Profit Margin	-56.48%
EBITDA Margin	-65.79%
EBIT Margin	-67.30%
FCF Margin	n/a

Dividends & Yields

Oryzon Genomics does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-23.15%
Shareholder Yield	-23.15%
Earnings Yield	-1.57%
FCF Yield	n/a

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Oryzon Genomics has an Altman Z-Score of 3.38 and a Piotroski F-Score of 2.

Altman Z-Score	3.38
Piotroski F-Score	2